Feasibility Study for Prolonged Nightly Fasting in Patients Treated for Liver Cancer

Prevention & Diagnostic Tools, Cancer Equities, Novel Therapeutics & Platforms

Nick Webster, PhD (UC San Diego)

Isabel Newton, MD, PhD (UC San Diego)

Adam Burgoyne, MD, PhD (UC San Diego)

The incidence of liver cancer is rising and the 5-year survival is only 15%. Recurrence is common after therapy with progression-free survival as low as 30-50% over 12 months. Our project intends to test a new nutritional intervention to see if recurrence in patients undergoing liver-directed therapy can be reduced. The intervention consists of limiting calorie intake to 8 hours during the day. We have shown this intervention to be effective at inhibiting liver cancer in preclinical models and hope to translate our findings to humans.

“Our research focuses on how early metabolic liver disease can progress to liver cancer. Our approaches include understanding the molecular events that occur early in disease that drive progression and oncogenesis, and developing interventions that can ameliorate the delirious effects of obesity and over-nutrition. With the support of Curebound, we aim to test our preclinical findings in humans with he hope of preventing recurrence of this deadly disease.” - Nick Webster